- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00146796
A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania
A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania
There is clear evidence diagnosis of malaria in much of Africa is sub-optimal and this has a negative impact on patient care. Many of those treated for malaria do not have it. Rapid diagnostic tests (RDTs) are dipsticks which diagnose malaria rapidly and accurately. The main objective of this trial is to determine by means of a randomised trial the impact of introducing RDTs into a standard outpatient setting in Tanzania has on the appropriate prescription of antimalarials. Other objectives are:
- To compare at high, moderate and low P.falciparum transmission intensity the sensitivity and specificity of malaria diagnosis using hospital slide results and RDTs, using research quality slides as the reference.
- To estimate the specificity of clinical diagnosis of malaria at high, moderate and low transmission intensity of P. falciparum.
- To compare the proportion of cases reported as slide-negative who are treated for malaria with the proportion of RDT-negative cases treated for malaria.
- To evaluate the cost effectiveness of introducing RDTs compared to current diagnostic practice in facilities with microscopic diagnosis of malaria at different levels of transmission of P.falciparum.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In each of the hospital outpatient facilities, patients consenting to participate will have a free malaria test but the test will be randomly assigned to hospital laboratory blood slide or RDT.
Sensitisation of sites and information displayed.
Before the start of the intervention study we will conduct meetings with the medical staff to explain the intervention and standard study procedure. We will provide information from published sources of the accuracy of 'Paracheck' compared to expert slide reading. Staff will be encouraged to use the RDT result in the same way that they would use a blood slide result of equivalent accuracy. We will consult with the Malaria Control Programme what additional information they would disseminate if they were deploying the tests.
Information will be displayed for patients attending the clinic that, for the period of the trial, malaria diagnosis will be free if requested by the clinic doctor. Patients consenting to participate will be randomly allocated to receive either a slide test or RDT. Patients who do not consent to participate will receive free hospital slide testing if requested by the clinic doctor and their treatment will follow routine practice.
Inclusion criteria
- All patients of any age attending the outpatient facility will be eligible to be considered for the trial with the exception of those who are admitted from outpatients to the ward or those who appear to the study clinical officer to be too distressed or ill to participate.
- The inclusion criteria will be a clinician decision to request a malaria test. The only exclusion to this will be where a clinician decides that they would prefer a hospital slide to the patient entering the trial- these cases will be noted but excluded from the trial.
Patient recruitment and informed consent All patients attending the clinic will be informed of the trial, either by means of a written information sheet or, if they cannot read verbally. They will be asked for verbal informed consent to provide baseline information before they are seen by the clinic doctor. Consenting patients will be assigned a screening number and asked questions as in the baseline study relating to personal and socio-economic characteristics and the main presenting symptom.
On exit from the consultation patients will be asked to show what treatment has been given and if a request for a malaria test has been made. Clinicians will indicate where they have a preference for a hospital slide- these patients will be excluded. Those eligible for the trial for whom a malaria test has been requested will be invited to participate in the trial. Further information about the trial will be provided, and they or their guardians will provide written informed consent (or witnessed where they cannot read). Those who consent to the trial will be assigned to RDT or hospital slide by opening an opaque sealed envelope within which will be a slip with the study allocation, generated by computer randomisation (see below, randomization)). These will be numbered, and the number will become the study number for the patient. Opening the envelope defines entering the trial. If on discovering the allocation the patient demands a different test this will be deemed a withdrawal from the trial and this outcome will be noted. Patients who withdraw will be offered standard care (see below- ethical issues).
If RDT has been allocated, the rapid test and malaria slide (for later expert reading) will be taken by a qualified member of the survey team who will label slides and RDTs with the patient's name, date and study number. The result of the RDT will be read and recorded by the research assistant and then the test given back to the patient to present to the doctor in a consultation. Clinic doctors will read the result and give treatment according to their clinical judgement.
If hospital slide has been requested the patient will present the slide request slip to the hospital laboratory according to normal clinic practice. In addition to taking a blood slide, laboratory staff will be asked to take a duplicate slide which will be retained, stained and double-read at a later time according to research methodology. The result will be given back to the patient for the review consultation according to normal clinic practice.
On exit from the consultation any patient who has been seen for a review of a blood slide or RDT result will be briefly interviewed to collect data on any treatment given or changed as a result of the review of results by the doctor.
Some patients may choose to leave the clinic once they have their result without a review consultation. This will be determined from their failure to appear on the exit survey.
Primary outcome:
The proportion of clinical treatments that are consistent with the parasitological diagnosis in those randomised to RDT compared to those randomised to hospital slide. This is a composite measure defined as an antimalarial given where the research slide is positive or no antimalarial given where the research slide is negative.
Secondary outcomes:
The proportion of slide negative cases given an antimalarial (overprescription of antimalarials) in the RDT arm compared to the standard care arm.
The proportion of slide positives not given an antimalarial who are slide positive (underprescription of antimalarials).
The proportion of cases who are treated for malaria on clinical grounds alone Sensitivity and specificity of RDT and hospital malaria slide compared to double read research slide results.
The proportion of patients receiving additional or alternative treatments to antimalarials following a negative blood slide or RDT result. This will inform cost-effectiveness models.
From 1 published study and 1 unpublished study we estimate that an antimalarial will be prescribed in at least 45% of cases who have had a negative blood slide result. This is expected to apply to all transmission settings. To detect a minimum 25% reduction we require a total of 820 at each transmission band.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Moshi, Tanzania, Private Bag
- Kilimanjaro Christian Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All patients of any age attending the outpatient facility will be eligible to be considered for the trial
- A clinician decision to request a malaria test.
Exclusion Criteria:
Where a clinician decides that they would prefer a hospital slide to the patient entering the trial- these cases will be noted but excluded from the trial.
Patients are admitted from outpatients to the ward Those who appear to the study clinical officer to be too distressed or ill to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Secondary Outcome Measures
Outcome Measure |
---|
The proportion of slide negative cases given an antimalarial (overprescription of antimalarials) in the RDT arm compared to the standard care arm.
|
The proportion of slide positives not given an antimalarial who are slide positive (underprescription of antimalarials).
|
Proportion of cases who are treated for malaria on clinical grounds alone
|
Sensitivity and specificity of RDT and hospital malaria slide compared to double read research slide results.
|
The proportion of patients receiving additional or alternative treatments to antimalarials following a negative blood slide or RDT result. This will inform cost-effectiveness models
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christopher Whitty, FRCP, London School of Hygiene and Tropical Medicine
Publications and helpful links
General Publications
- Reyburn H, Mbatia R, Drakeley C, Carneiro I, Mwakasungula E, Mwerinde O, Saganda K, Shao J, Kitua A, Olomi R, Greenwood BM, Whitty CJ. Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study. BMJ. 2004 Nov 20;329(7476):1212. doi: 10.1136/bmj.38251.658229.55. Epub 2004 Nov 12.
- Reyburn H, Mbakilwa H, Mwangi R, Mwerinde O, Olomi R, Drakeley C, Whitty CJ. Rapid diagnostic tests compared with malaria microscopy for guiding outpatient treatment of febrile illness in Tanzania: randomised trial. BMJ. 2007 Feb 24;334(7590):403. doi: 10.1136/bmj.39073.496829.AE. Epub 2007 Jan 26.
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ITIMVG38
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malaria
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst and other collaboratorsRecruitingPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaLao People's Democratic Republic
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaCompletedPlasmodium Falciparum Malaria | Plasmodium Vivax MalariaPeru
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanCompletedVivax Malaria | Uncomplicated Falciparum MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaEthiopia, Bangladesh, Indonesia
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...Completed
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... and other collaboratorsCompletedMalaria | Vivax Malaria | Falciparum MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...CompletedVivax Malaria | Falciparum MalariaIndonesia
-
University of IbadanShin Poong Pharm Co Ltd 161 yoksam-ro, Gangnam-Gu Seoul 135-925, Korea; Institute...CompletedPlasmodium Falciparum Malaria | Uncomplicated Malaria | Malaria FeverNigeria
-
Research Institute for Tropical Medicine, PhilippinesWorld Health OrganizationCompletedTES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014 (TES)Malaria | Vivax Malaria | Falciparum Malaria | Malaria Recrudescence
Clinical Trials on Rapid diagnostic test for malaria
-
Institute of Tropical Medicine, BelgiumWithdrawn
-
Centro per le Malattie TropicaliInstitute of Tropical Medicine, BelgiumCompleted
-
London School of Hygiene and Tropical MedicineGhana Health ServicesCompleted
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Moi UniversityCompleted
-
Centro de Investigação em Saúde de ManhiçaUniversity of California, San Francisco; Barcelona Institute for Global Health and other collaboratorsRecruitingMalaria | Malaria in Pregnancy | Malaria,FalciparumMozambique
-
DBL -Institute for Health Research and DevelopmentLondon School of Hygiene and Tropical Medicine; Ministry of Health, Uganda; Artemisinin-based...Completed
-
London School of Hygiene and Tropical MedicineHealthNet TPO; Health Protection and Research Organisation; Medical Emergency...CompletedPneumonia | Fever | Malaria | Acute Febrile IllnessAfghanistan
-
Karolinska University HospitalMuhimbili University of Health and Allied SciencesCompletedUncomplicated Plasmodium Falciparum MalariaTanzania
-
Abbott Rapid DxBill and Melinda Gates FoundationCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted